Medtronic plc (NYSE:MDT) Shares Bought by CreativeOne Wealth LLC

CreativeOne Wealth LLC increased its holdings in Medtronic plc (NYSE:MDT) by 279.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,672 shares of the medical technology company’s stock after buying an additional 15,225 shares during the quarter. CreativeOne Wealth LLC’s holdings in Medtronic were worth $1,861,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MDT. iA Global Asset Management Inc. purchased a new stake in Medtronic in the 1st quarter worth approximately $513,000. Citizens Financial Group Inc. RI boosted its position in Medtronic by 15.4% in the 1st quarter. Citizens Financial Group Inc. RI now owns 3,518 shares of the medical technology company’s stock worth $307,000 after purchasing an additional 470 shares in the last quarter. Cetera Advisors LLC boosted its position in Medtronic by 63.3% in the 1st quarter. Cetera Advisors LLC now owns 83,977 shares of the medical technology company’s stock worth $7,319,000 after purchasing an additional 32,564 shares in the last quarter. Cetera Advisor Networks LLC boosted its position in Medtronic by 4.5% in the 1st quarter. Cetera Advisor Networks LLC now owns 252,106 shares of the medical technology company’s stock worth $21,971,000 after purchasing an additional 10,890 shares in the last quarter. Finally, Cambridge Trust Co. boosted its position in Medtronic by 4.3% in the 1st quarter. Cambridge Trust Co. now owns 19,936 shares of the medical technology company’s stock worth $1,737,000 after purchasing an additional 813 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

MDT has been the topic of a number of recent analyst reports. Royal Bank of Canada upgraded Medtronic from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $98.00 to $105.00 in a research report on Thursday, October 10th. Oppenheimer raised their target price on Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 21st. Sanford C. Bernstein raised their price objective on Medtronic from $96.00 to $97.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 20th. Daiwa America raised Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. Finally, Evercore ISI lifted their price objective on Medtronic from $100.00 to $104.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $95.27.

Medtronic Trading Up 0.7 %

MDT opened at $86.27 on Friday. The firm has a market cap of $110.62 billion, a price-to-earnings ratio of 26.38, a price-to-earnings-growth ratio of 2.44 and a beta of 0.84. Medtronic plc has a 52 week low of $75.96 and a 52 week high of $92.68. The business’s 50 day moving average is $88.75 and its two-hundred day moving average is $84.97. The company has a quick ratio of 1.39, a current ratio of 1.84 and a debt-to-equity ratio of 0.51.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.25 by $0.01. The company had revenue of $8.40 billion for the quarter, compared to analyst estimates of $8.27 billion. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 earnings per share. On average, research analysts predict that Medtronic plc will post 5.46 EPS for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.